Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Davide Matino

6PUBLICATIONS
13CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

Sort by Publication Date:
|Mar 24, 2026
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Omotola O Olasupo, Noella Noronha, Megan S Lowe

|Jan 19, 2026
Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry-Based Matched Cohort Study.

Federico Germini, Arun Keepanasseril, Quazi Ibrahim

|Nov 20, 2025
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study.

Davide Matino, Laurent Frenzel, Ali Bulent Antmen

|Oct 14, 2025
Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada.

Davide Matino, Anthony K C Chan, Kay Decker

|Feb 21, 2024
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.

Davide Matino, Federico Germini, Anthony K C Chan

|Feb 19, 2024
Recombinant factor IX Fc for the treatment of hemophilia B.

Rolf Ljung, Davide Matino, Amy D Shapiro

Pageof 1

Frequent Collaborators

3 joint publications

Alfonso Iorio

2 joint publications

Andrea N Edginton

2 joint publications

Arun Keepanasseril

1 joint publications

Rolf Ljung

1 joint publications

Amy D Shapiro

1 joint publications

Pierre Chelle

1 joint publications

Laurent Frenzel

1 joint publications

Jan Astermark

1 joint publications

Kaan Kavakli

1 joint publications

Stephanie P'ng

Frequent Collaborators

3 joint publications

Alfonso Iorio

2 joint publications

Andrea N Edginton

2 joint publications

Arun Keepanasseril

1 joint publications

Rolf Ljung

Top Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on : Sep 30, 2021

7.8K
The Generation of Closed Femoral Fractures in Mice: A Model to Study Bone Healing
05:53

The Generation of Closed Femoral Fractures in Mice: A Model to Study Bone Healing

Published on : Aug 16, 2018

16.2K
See more related videos

Top Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on : Sep 30, 2021

7.8K
The Generation of Closed Femoral Fractures in Mice: A Model to Study Bone Healing
05:53

The Generation of Closed Femoral Fractures in Mice: A Model to Study Bone Healing

Published on : Aug 16, 2018

16.2K
See more related videos